Y-mAbs Therapeutics, Inc. (YMAB): Price and Financial Metrics


Y-mAbs Therapeutics, Inc. (YMAB): $36.22

-1.42 (-3.77%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

YMAB POWR Grades


  • Sentiment is the dimension where YMAB ranks best; there it ranks ahead of 80.95% of US stocks.
  • YMAB's strongest trending metric is Growth; it's been moving up over the last 31 weeks.
  • YMAB's current lowest rank is in the Momentum metric (where it is better than 9.33% of US stocks).

YMAB Stock Summary

  • YMAB's went public 2.74 years ago, making it older than only 6.93% of listed US stocks we're tracking.
  • The ratio of debt to operating expenses for Y-mAbs Therapeutics Inc is higher than it is for about just 6.62% of US stocks.
  • With a price/sales ratio of 57.66, Y-mAbs Therapeutics Inc has a higher such ratio than 94.85% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Y-mAbs Therapeutics Inc are ECOM, STMP, MXL, HROW, and GPX.
  • Visit YMAB's SEC page to see the company's official filings. To visit the company's web site, go to www.ymabs.com.

YMAB Price Target

For more insight on analysts targets of YMAB, see our YMAB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $57.88 Average Broker Recommendation 1.3 (Strong Buy)

YMAB Stock Price Chart Interactive Chart >

Price chart for YMAB

YMAB Price/Volume Stats

Current price $36.22 52-week high $55.22
Prev. close $37.64 52-week low $24.77
Day low $35.33 Volume 1,207,000
Day high $37.34 Avg. volume 297,584
50-day MA $32.00 Dividend yield N/A
200-day MA $39.98 Market Cap 1.58B

Y-mAbs Therapeutics, Inc. (YMAB) Company Bio


Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. The company has a license and research collaboration agreement with Memorial Sloan-Kettering Cancer Center. Y-mAbs Therapeutics, Inc. was founded in 2015 and is based in New York, New York.


YMAB Latest News Stream


Event/Time News Detail
Loading, please wait...

YMAB Latest Social Stream


Loading social stream, please wait...

View Full YMAB Social Stream

Latest YMAB News From Around the Web

Below are the latest news stories about Y-mAbs Therapeutics Inc that investors may wish to consider to help them evaluate YMAB as an investment opportunity.

Y-mAbs Announces Frontline Data for DANYELZA® (naxitamab-gqgk) in High-Risk Neuroblastoma

NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that Dr. Jaume Mora, M.D., Ph.D. from SJD Barcelona Children's Hospital will present frontline data for DANYELZA and GM-CSF for consolidation of high-risk neuroblastoma (“HR-NB”) patients in complete re

Yahoo | June 4, 2021

Y-mAbs Announces Update on Omburtamab for DIPG

NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that Dr. Mark Souweidane, Memorial Sloan Kettering Cancer Center (“MSK”) and Weill Cornell Medicine will present interim phase 1 dose-escalation data for omburtamab for diffuse intrinsic pontine glioma

Yahoo | June 4, 2021

Y-mAbs Signs Antibodies’ Distribution Deal With Adium; Street Says Buy

Y-mAbs Therapeutics (YMAB), the commercial-stage biopharmaceutical company, revealed that it has inked a distribution agreement with Adium Pharma S.A. for DANYELZA (naxitamab-gqgk) and omburtamab (if approved), the company’s antibodies, in Latin America. The financial terms of the agreement were not disclosed. Per the terms of the deal, Adium’s sales and marketing proficiency will be used in distributing DANYELZA and omburtamab in the territory. Furthermore, registration files will be submitted by Adium on behalf of Y-mAbs in certain parts of the territory. All other global unpartnered regions remain with the company.

Priti Ramgarhia on TipRanks | May 20, 2021

Y-mAbs inks exclusive distribution agreement with Adium Pharma

Y-mAbs Therapeutics (YMAB) has entered into an agreement with Adium Pharma to be the exclusive distributor in Latin America of the company’s DANYELZA treatment.DANYELZA (naxitamab-gqgk) is indicated, in combination with granulocyte-macrophage colony-stimulating factor (“GM-CSF”), for the treatment of certain patients with relapsed or refractory high-risk neuroblastoma.The distribution agreement includes the territories of Argentina, Belize, Bolivia, Brazil, Chile,...

Seeking Alpha | May 19, 2021

Y-mAbs Announces Update on SADA Technology

NEW YORK, May 13, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that Nai-Kong V. Cheung, MD, PhD, Enid A. Haupt Endowed Chair, Pediatric Oncology, Memorial Sloan Kettering Cancer Center (“MSK”) will present a research update on the Company’s SADA technology platform at PEGS Boston Virtual Conference on May 13, 2021 at 1:20 p.m. Eastern Time. The SADA technology was licensed by the Company from MSK and the Massachusetts Institute of Technology (“MIT”). Dr. Cheung’s presentation will focus on cancer therapeutics failing in development because of dose-limiting ...

Yahoo | May 13, 2021

Read More 'YMAB' Stories Here

YMAB Price Returns

1-mo 0.50%
3-mo 3.49%
6-mo -32.34%
1-year -24.75%
3-year N/A
5-year N/A
YTD -26.84%
2020 58.43%
2019 53.64%
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.833 seconds.